Skip to main content

Table 4 Subgroup analysis of second-line abatacept effectiveness by reasons for treatment failure

From: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

Measure

Baseline

Change from baseline to month 6

Remission at month 6

LDAS at month 6

 

N

Mean (SD)

N

Mean (95% CI)

N

Percent (95% CI)

N

Percent (95% CI)

 

Primary inefficacy

 

DAS28 (ESR)

129

5.6 (1.3)

113

−1.5 (−1.7, –1.2)

119

17.6 (10.8, 24.5)

119

29.4 (21.2, 37.6)

DAS28 (CRP)

35

5.2 (1.3)

26

−1.3 (−2.0, –0.7)

32

12.5 (1.0, 24.0)

32

34.4 (17.9, 50.8)

CDAI

140

32.1 (13.1)

129

−13.9 (−16.3, –11.5)

136

2.9 (0.1, 5.8)

136

27.9 (20.4, 35.5)

 

Secondary inefficacy

 

DAS28 (ESR)

249

5.6 (1.1)

219

−1.4 (−1.6, –1.2)

240

10.4 (6.6, 14.3)

240

25.0 (19.5, 30.5)

DAS28 (CRP)

74

5.5 (1.3)

55

−1.6 (−2.0, –1.3)

68

20.6 (11.0, 30.2)

68

38.2 (26.7, 49.8)

CDAI

295

32.5 (13.0)

279

−15.4 (−17.1, –13.8)

288

4.2 (1.9, 6.5)

288

29.5 (24.2, 34.8)

 

Safety and tolerability

 

DAS28 (ESR)

91

5.5 (1.3)

84

−1.5 (−1.8, –1.2)

98

18.4 (10.7, 26.0)

98

29.6 (20.6, 38.6)

DAS28 (CRP)

27

4.8 (1.4)

22

−1.5 (−2.2, –0.9)

26

30.8 (13.0, 48.5)

26

42.3 (23.3, 61.3)

CDAI

121

30.4 (13.4)

115

−15.2 (−17.6, –12.8)

119

8.4 (3.4, 13.4)

119

38.7 (29.9, 47.4)

  1. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate.